Icosapent Ethyl (IPE) Archives - Medical Conferences

Icosapent ethyl did not reduce the risk of hospitalisation in COVID-19

Presented By

Dr Rafael Díaz, Estudios Clínicos Latinoamérica, Argentina

Trial

PREPARE IT-2

Conference

AHA 2021

Type

Peer-reviewed article

14 January 2022 16:37

REDUCE-IT: Cardiovascular risk reduction with icosapent ethyl in PAD

Presented By

Dr Deepak Bhatt, Brigham and Women’s Hospital, Boston, USA

Trial

Phase 3, REDUCE-IT

Conference

AHA 2021

Type

Peer-reviewed article

14 January 2022 15:36

STRENGTH trial fails to demonstrate cardioprotective effect of omega-3 fatty acids

Presented By

Dr Steven Nissen, Cleveland Clinic, USA

Trial

STRENGTH, REDUCE-IT

Conference

ACC 2021

Type

Peer-reviewed article

9 July 2021 23:25

Reduced progression of coronary atherosclerosis with icosapent ethyl

Presented By

Prof. Matthew Budoff, Harbor-UCLA Medical Center, USA

Trial

EVAPORATE trial

Conference

ESC 2020

Type

Peer-reviewed article

5 November 2020 12:48

Higher serum levels of eicosapentaenoic acid correlate with reduced CV events

Presented By

Dr D. Bhatt, Brigham and Women's Hospital, USA

Trial

REDUCE-IT EPA analysis

Conference

ACC 2020

Type

Peer-reviewed article

8 September 2020 13:44

Icosapent ethyl plus statins reduces total plaque volume

Presented By

Prof. Matthew J. Budoff, UCLA, USA

Trial

EVAPORATE

Conference

AHA 2019

Type

Peer-reviewed article

26 February 2020 20:55

Convincing evidence of the role of icosapent in reducing subsequent CV events

Presented By

Prof. Deepak Bhatt, Brigham and Women’s Hospital, USA

Trial

REDUCE-IT

Conference

ACC 2019

Type

Peer-reviewed article

6 June 2019 13:57